← SITE005 (FRA)

SITE005-0324

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2023-03-26
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal

Adverse events

mild assessed 2026-08-18

Grade 1 Rash — outcome: RECOVERED/RESOLVED; onset 2023-06-22 (study day 80); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-07-14 (study day 102); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-11-03 (study day 214); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-04-11 (study day 374); relationship: N

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-11-10 (study day 587); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.